Antibacterial Drugs Market

SKU: DMPH1511 | Last Updated On: Sep 21 2022 | Available Formats

>Antibacterial Drugs Market Expected to reach a high CAGR of 5% By 2029:

Antibacterial Drugs Market is segmented By Action Type (Bacteriostatic, Bactericidal, By Drug Type (Beta lactams, Aminoglycosides, Tetracyclines, Macrolides, Sulfonamide, Quinolones, Others), By Route of Administration (Oral, Parenteral, others), By Drug Mechanism (Cell Wall Synthesis Inhibitors, Plasma Membrane Inhibitors, Protein Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, Others), By Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Antibacterial Drugs Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5% during the forecast period (2022-2029).

Antibacterial Drugs Market

Metrics

Details

Market CAGR

5%

Segments Covered

By Action Type, By Drug Type, By Route of Administration, By Drug Mechanism, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Antibacterial medications can be made from bacteria or molds, or they can be generated from scratch. These drugs either kill or slow the growth of germs. Antibacterial medications treat urinary infections caused by E. coli, S. aureus, Streptococcus pyogenes, and other bacterial infections. Influenza is a contagious respiratory ailment caused by the influenza virus. Antibacterial medications are important in advanced healthcare since they are widely utilized in treating and preventing infectious diseases such as influenza (flu) and the common cold. Antibacterial medications work by killing or preventing microbial development.

Market Dynamics

Antibacterial drugs market growth is driven by increased demand for antibacterial drugs due to rising prevalence of bacterial infections globally, the development of novel therapies, an increase in government policies and increased funds from other public bodies.

The increasing speed of development and commercialization of antibacterial drugs is expected to drive market growth.

The growing threat posed by multidrug-resistant gram-negative organisms (MDR-GNBs) is increasing the urgency with which antibacterial medications are being developed worldwide. Pharmaceutical producers will benefit from upcoming regulatory improvements that will reduce R&D costs and incentivize novel medication identification. A Product and Pipeline Analysis of the Antibacterial Pharmaceuticals Market, published by Frost & Sullivan, reveals that approximately 80% of drugs now in the pipeline are from smaller pharmaceutical and biotech businesses, half of which do not have any commercialized products on the market. The only three established pharmaceutical companies in the antibacterial medicine space are GlaxoSmithKline, AstraZeneca, and Merck & Co. Moreover, it isn't easy to discover new antibacterial medications and uncover unique molecules that can successfully target germs. Big pharma corporations, formerly leaders, are closing down their antimicrobial research centers due to the high risk of failure and costly R&D costs. As a result, organizations such as the Food and Drug Administration (FDA) and the Infectious Diseases Society of America are launching several programs to entice corporations to return to antibacterial R&D. The recently enacted Generating Antibiotic Incentives Now (GAIN) Act is expected to promote more efficient clinical trials and lower market entry barriers. Combating Bacterial Resistance in Europe (COMBACTE) and TRANSLOCATION (molecular basis of bacterial cell wall permeability) are two projects launched by the Innovative Medicines Initiative (IMI) in Europe that demonstrate an unprecedented collaboration between industry, biotech organizations, and academia to combat antibiotic resistance.

Furthermore, collaborations between businesses, academia, investors, and key opinion leaders in the form of public-private partnerships can efficiently address the large unmet clinical and commercial needs in the antibacterial pharmaceutical market and accelerate commercialization.

Restraint:

However, genetic mutations, the toxicity of antibacterial drugs are expected to hamper the market. For instance, spontaneous mutations acquired from other bacteria through horizontal gene transfer make the bacteria resistant to the antibiotic. Also, toxicities related to antibacterial drugs like photosensitivity caused by fluoroquinolones are restraining the market.

Industry Analysis

The antibacterial drugs market provides in-depth market analysis based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Beta lactams segment is expected to hold the largest market share in the antibacterial drugs market.

The Beta-lactam antibiotics segment accounted for the largest market share in 2021. The segment benefits because β-Lactams are one of the most often prescribed antibiotic classes for antibacterial treatment today. They restrict bacterial growth by blocking PBPs, which are required for cross-linking during cell wall formation. Moreover, there are recent FDA approvals and pharmaceutical companies that have promising pipelines that are driving the market in the forecast period. For instance, on February 12, 2021, Avycaz, a new intravenous combination antibacterial medication, was approved by the US Food and Drug Administration (FDA) for treating complex infections. It comprises ceftazidime, a third-generation cephalosporin beta-lactam antibiotic, and avibactam, a novel beta-lactamase inhibitor. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global antibacterial drugs market.

North America accounted for the largest market share in 2021. The rising prevalence of infectious diseases, increased antibiotic resistance, government initiatives, increased regional FDA approvals, high treatment rates, and improved diagnosis. For instance, according to the World Health Organization, coronavirus cases were confirmed until September 12, 2022, with 230,868 cases in the United States. Moreover, Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical firm, said in June 2021 that the FDA accepted the company's supplemental new drug application (sNDA) for the oral-only dosage regimen of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP). In addition, in 2021, Melinta Therapeutics LLC, a biopharmaceutical company based in the United States, received FDA approval for its new drug KIMYRSA (oritavancin), a lipoglycopeptide antibiotic indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Therefore, it has increased the adoption of antibiotics in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the antibacterial drugs market are Pfizer, GlaxoSmithKline (GSK) and Merck & Co., Novartis AG, Sanofi, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Allergan, Cempra and Insmed.

GlaxoSmithKline PLC:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, and older people and travel vaccines

Product Portfolio: 

Amoxil: It treats bacterial infections, such as chest infections (including pneumonia) and dental abscesses. It can also be used with other antibiotics and medicines to treat stomach ulcers.

The global antibacterial drugs market report would provide an access to an approx. 45+market data table, 40+figures

Frequently Asked Questions

What is the Projected CAGR value of the Antibacterial Drugs Market?

Antibacterial Drugs Market is expected to grow at a CAGR of 5% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Antibacterial Drugs Market during 2022-2029

Which is the fastest growing region in the Antibacterial Drugs Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Antibiotics Market

Antimicrobial Therapeutics Market

Antifibrinolytic Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest